Physician profile
Mena Said
NPI 1053859678
$5,838.60
in general payments reported to CMS, 2019-2025
19 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 89% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $566 · 2023: $1,879 · 2024: $1,447 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,661 · Travel and Lodging: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.48 |
| Travel and Lodging | $1,611.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,881.92 | 2023-2024 | Inspire |
| Stryker Corporation | $992.97 | 2022-2025 | Scopis Ent, Latera, Clarifix Cryotherapy Device |
| Genzyme Corporation | $614.43 | 2024-2025 | |
| Integra Lifesciences Corporation | $532.44 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Glaxosmithkline, LLC. | $530.22 | 2024-2025 | Nucala |
| Merz North America, INC. | $331.34 | 2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $254.53 | 2025 | Tezspire |
| Neurent Medical Limited | $112.25 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Pfizer INC. | $91.68 | 2025 | |
| Optinose US, INC. | $80.27 | 2024 | |
| Cochlear Americas | $76.14 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Medtronic, INC. | $70.88 | 2024-2025 | Bizact, Pteye Parathyroid Detection System, Propel |
| Karl Storz Endoscopy-America | $62.83 | 2024-2025 | Rhinoforce |
| Regeneron Healthcare Solutions, INC. | $60.18 | 2025 | Dupixent |
| Smith+Nephew, INC. | $47.24 | 2025 | Tula, Ent Sinus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $31.91 | 2025 | |
| Paratek Pharmaceuticals, INC. | $25.06 | 2025 | Xhance |
| Amgen INC. | $24.51 | 2025 | Tezspire |
| Therapeuticsmd, INC. | $17.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mena Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.